References
- Mattia C, Coluzzi F, Celidonio L, Vellucci R. Bone pain mechanism in osteoporosis: a narrative review. Clin Cases Miner Bone Metab 2016; 13: 97-100.
- Lee YJ, Park CH, Lee YK, Ha YC, Koo KH. Which bisphosphonate? It's the compliance!: decision analysis. J Bone Metab 2016; 23: 79-83. https://doi.org/10.11005/jbm.2016.23.2.79
- Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25: 2359-81. https://doi.org/10.1007/s00198-014-2794-2
- Kim SY, Ok HG, Birkenmaier C, Kim KH. Can denosumab be a substitute, competitor, or compliment to bisphosphonates? Korean J Pain 2017; 30: 86-92. https://doi.org/10.3344/kjp.2017.30.2.86
- Tetsunaga T, Tetsunaga T, Nishida K, Tanaka M, Sugimoto Y, Takigawa T, et al. Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures. J Orthop Sci 2017; 22: 230-6. https://doi.org/10.1016/j.jos.2016.11.017